Skip to main content
SpringerLink
Log in

Antiarrhythmic Drug Classifications

A Critical Appraisal of their History, Present Status, and Clinical Relevance

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Classifications of antiarrhythmic drugs have developed because of a need to organise the large number of agents available according to pharmacological properties of clinical relevance. The current classification is a hybrid of classification systems developed in the early 1970s. It subdivides drugs according to 4 major pharmacological actions: (a) depression of phase 0 sodium current; (b) antagonism of adrenergic effects on the heart; (c) prolongation of action potential duration; and (d) calcium channel blockade. Further subdivision of sodium channel blockers is based on the kinetics of sodium channel blockade and drug effects on action potential duration.

A critical analysis of selected aspects of the clinical actions of antiarrhythmic drugs indicates the value of the current classification, as well as some limitations in its ability to separate drugs into distinct groups with characteristic clinical properties. The strengths of the current classification are due to the clinical importance of the pharmacological properties on which it is based. These result in electrophysiological actions, indications, and adverse effects that are typical for each group of drugs. The limitations of the current system relate to the propensity of individual drugs to have actions of more than one class simultaneously, the way that the various actions of a given drug are dependent on concentration, rate, and tissue type, and to problems in subclass definition.

Some of these shortcomings could be alleviated by returning to the concept, originally put forward by Singh and Vaughan Williams, of classes of drug action rather than classes of drug per se. This approach would be pharmacologically more realistic than trying to assign each antiarrhythmic agent to a single unique class, would be better able to incorporate the complexities of drug action, and would potentially be more flexible. The wide use of antiarrhythmic drug classifications attests to their value, and suggests that they are likely to continue to be important in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abdollah H, Brugada P, Green M, Wehr M, Wellens HJJ. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. American Journal of Cardiology 54: 544–549, 1984

    Article  PubMed  CAS  Google Scholar 

  • Adgey AAJ, Scott ME, Allen JD, Nelson PG, Geddes JS, et al. Management of ventricular fibrillation outside the hospital. Lancet 1: 1169–1171, 1969

    Article  PubMed  CAS  Google Scholar 

  • Adhar GC, Swerdlow CD, Lance BL, Clay D, Bardy GH, et al. Tocainide for drug-resistant sustained ventricular tachyar-rhythmias. Journal of the American College of Cardiology 11: 124–131, 1988

    Article  PubMed  CAS  Google Scholar 

  • Anastasiou-Nana MI, Anderson JL, Askins JC, Gilbert EM, Nanas JN, et al. Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. American Heart Journal 114:288–296, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Anastasiou-Nana MI, Anderson JL, Stewart JR, Crevey BJ, Yanowitz FG, et al. Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect. American Heart Journal 113: 1071–1077, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, et al. Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses. Journal of the American College of Cardiology 8: 752–762, 1986

    Article  PubMed  CAS  Google Scholar 

  • Anderson JL, Lutz JR, Allison SB. Electrophysiologic and anti-arrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. Journal of the American College of Cardiology 2: 105–114, 1983

    Article  PubMed  CAS  Google Scholar 

  • Anderson JL, Mason JW, Winkle RA, Meffin PJ, Fowles RE, et al. Clinical electrophysiologic effects of tocainide. Circulation 57: 685–691, 1978

    Article  PubMed  CAS  Google Scholar 

  • Anderson JL, Stewart JR, Perry BA, van Hamersveld DD, Johnson TA, et al. Oral flecainide acetate for the treatment of ventricular arrhythmias. New England Journal of Medicine 305: 473–477, 1981

    Article  PubMed  CAS  Google Scholar 

  • Arnsdorf MF. Electrophysiologic properties of antidysrhythmic drugs as a rational basis for therapy. Medical Clinics of North America 60: 213–232, 1976

    PubMed  CAS  Google Scholar 

  • Bacaner MB. Treatment of ventricular fibrillation and other acute arrhythmias with bretylium tosylate. American Journal of Cardiology 21: 530–543, 1968

    Article  PubMed  CAS  Google Scholar 

  • Bär FW, Farré J, Ross D, Vanagt EJ, Gorgels AP, et al. Electrophysiological effects of lorcainide, a new antiarrhythmic drug. British Heart Journal 45: 292–298, 1981

    Article  PubMed  Google Scholar 

  • Barrett PA, Laks MM, Mandel WJ, Yamaguchi I. The electrophysiologic effects of intravenous lidocaine in the Wolff-Parkinson-White syndrome. American Heart Journal 100: 23–33, 1980

    Article  PubMed  CAS  Google Scholar 

  • Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. American Heart Journal 117: 151–159, 1989

    Article  PubMed  Google Scholar 

  • Befeler B, Castellanos Jr A, Wells DE, Vagueiro MC, Yeh BK. Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate. American Journal of Cardiology 35: 282–287, 1975

    Article  PubMed  CAS  Google Scholar 

  • Bekheit S, Murtagh JG, Morton P, Fletcher E. Effect of lignocaine on conducting system of human heart. British Heart Journal 35: 305–311, 1973

    Article  PubMed  CAS  Google Scholar 

  • β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Journal of the American Medical Association 247: 1707–1714, 1982

    Article  Google Scholar 

  • Bigger Jr JT, Bassett AL, Hoffman BF. Electrophysiological effects of diphenylhydantoin on canine Purkinje fibers. Circulation Research 22: 221–236, 1968

    Article  PubMed  CAS  Google Scholar 

  • Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69: 250–258, 1984

    Article  PubMed  Google Scholar 

  • Bigger Jr JT, Jaffe CC. The effect of bretylium tosylate on the electrophysiologic properties of ventricular muscle and Purkinje fibers. American Journal of Cardiology 27: 82–92, 1971

    Article  PubMed  CAS  Google Scholar 

  • Bigger Jr JT, Mandel WJ. Effect of lidocaine on conduction in canine Purkinje fibers and at the ventricular muscle-Purkinje fiber junction. Journal of Pharmacology and Experimental Therapeutics 172: 239–254, 1970a

    PubMed  CAS  Google Scholar 

  • Bigger Jr JT, Mandel WJ. Effect of lidocaine on the electrophysiological properties of ventricular muscle and Purkinje fibers. Journal of Clinical Investigation 49: 63–77, 1970b

    Article  PubMed  CAS  Google Scholar 

  • Bigger Jr JT, Sahar DI. Clinical types of proarrhythmic response to antiarrhythmic drugs. American Journal of Cardiology 59: 2E-9E, 1987

    Article  Google Scholar 

  • Birkhead JS, Vaughan Williams EM. Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods. British Heart Journal 39: 657–660, 1977

    Article  PubMed  CAS  Google Scholar 

  • Bloomfield SS, Romhilt DW, Chou TC, Fowler NO. Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. New England Journal of Medicine 285: 979–986, 1971

    Article  PubMed  CAS  Google Scholar 

  • Brennan FJ, Cranefield PF, Wit AL. Effects of lidocaine on slow response and depressed fast response action potentials of canine cardiac Purkinje fibers. Journal of Pharmacology and Experimental Therapeutics 204: 312–324, 1978

    PubMed  CAS  Google Scholar 

  • Brennan FJ, Wit AL. Effects of lidocaine on electrophysiological properties of Purkinje fibers surviving acute myocardial infarction. Abstract. Circulation 48 (Suppl. IV): IV–148, 1973

    Google Scholar 

  • Brodsky MA, Allen BJ, Luckett CR, Capparelli EV, Wolff LJ, et al. Antiarrhythmic efficacy of solitary beta-adrenergic blockade for patients with sustained ventricular tachyarrhythmias. American Heart Journal 118: 272–280, 1989

    Article  PubMed  CAS  Google Scholar 

  • Broekhuysen J. Amiodarone: historical background. In Breithardt et al. (Eds) New aspects in the medical treatment of tachyarrhythmias, pp. 42–45, Urban and Schwarzenburg, Munich, 1983

    Google Scholar 

  • Cain ME. The role of newer antiarrhythmic drugs in the management of patients with ventricular arrhythmias. Angiology 39: 668–683, 1988

    PubMed  CAS  Google Scholar 

  • Campbell RWF, Dolder MA, Prescott LF, Talbot RG, Murray A, et al. Ventricular arrhythmias after acute myocardial infarction treated with procainamide or mexiletine. Postgraduate Medical Journal 53 (Suppl. 1): 150–153, 1977

    PubMed  Google Scholar 

  • Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovascular Research 17: 344–352, 1983

    Article  PubMed  CAS  Google Scholar 

  • Caracta AR, Damato AN, Josephson ME, Ricciutti MA, Gallagher JJ, et al. Electrophysiologic properties of diphenylhydantoin. Circulation 47: 1234–1241, 1973

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet E. Electrophysiological effects of encainide on isolated cardiac muscle and Purkinje fibers and on the Langendorff-perfused guinea-pig heart. European Journal of Pharmacology 61: 247–262, 1980

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. Journal of Pharmacology and Experimental Therapeutics 232: 817–825, 1985

    PubMed  CAS  Google Scholar 

  • Carmeliet E. Activation block and trapping of penticainide, a disopyramide analogue, in the Na+ channel of rabbit cardiac Purkinje fibers. Circulation Research 63: 50–60, 1988

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet E, Janssen PAJ, Marsboom R, Van Nueten JM, Xhonneux R. Antiarrhythmic, electrophysiologicl and hemodynamic effects of lorcainide. Archives Internationales de Pharmacodynamie 231: 104–130, 1978

    CAS  Google Scholar 

  • CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 321: 406–412, 1989

    Article  Google Scholar 

  • Chamberlain DA, Julian DG, Boyle DMcC, Jewitt DE, Campbell RWF, et al. Oral mexiletine in high-risk patients after myocardial infarction. Lancet 2: 1324–1327, 1980

    Article  PubMed  CAS  Google Scholar 

  • Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive, blockade of adrenoreceptors. British Journal of Pharmacology 39: 668–674, 1970

    Article  PubMed  CAS  Google Scholar 

  • Chilson DA, Heger JJ, Zipes DP, Browne KF, Prystowsky EN. Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. Journal of the American College of Cardiology 5: 1407–1413, 1985

    Article  PubMed  CAS  Google Scholar 

  • Chimienti M, Moizi M, Salerno JA, Klersy C, Guasti L, et al. Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation. European Heart Journal 8: 282–290, 1987

    PubMed  CAS  Google Scholar 

  • Chopra MP, Thadani U, Portal RW, Aber CP. Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial. British Medical Journal 3: 668–670, 1971

    Article  PubMed  CAS  Google Scholar 

  • Clark M, Friday K, Anderson J, Jackman W, Aliot E, et al. Drug induced torsades de pointes: high concordance rate among type 1A antiarrhythmic drugs and amiodarone. Abstract. Journal of the American College of Cardiology 5: 450, 1985

    Google Scholar 

  • Cobb LA, Werner JA, Trobaugh GB. Sudden cardiac death. I. A decade’s experience with out-of-hospital resuscitation. Modern Concepts in Cardiovascular Disease 49: 31–36, 1980

    CAS  Google Scholar 

  • Collaborative Group. Phenytoin after recovery from myocardial infarction: controlled trial in 568 patients. Lancet 2: 1055–1057, 1971

    Google Scholar 

  • Connolly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, et al. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. American Journal of Cardiology 52: 1208–1213, 1983

    Article  PubMed  CAS  Google Scholar 

  • Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Prevention of recurrent atrial fibrillation by quinidine: a metanalysis of randomized trials. Abstract. Circulation 80 (Suppl. II): II–633, 1989

    Google Scholar 

  • Coraboeuf E, Deroubaix E, Coulombe A. Effect of tetrodotoxin on action potentials of the conducting system in the dog heart. American Journal of Physiology 236: H561–H567, 1979

    PubMed  CAS  Google Scholar 

  • Cowan JC, Vaughan Williams EM. Characterization of a new oral antiarrhythmic drug, flecainide (R818). European Journal of Pharmacology 73: 333–342, 1981

    Article  CAS  Google Scholar 

  • Damato AN, Berkowitz WD, Patton RD, Lau SH. The effect of diphenylhydantoin on atrioventricular and intraventricular conduction in man. American Heart Journal 79: 51–56, 1970

    Article  PubMed  CAS  Google Scholar 

  • Danilo Jr P, Hordof AJ, Rosen MR. Effects of disopyramide on electrophysiologic properties of canine cardiac Purkinje fibers. Journal of Pharmacology and Experimental Therapeutics 201: 701–710, 1977

    PubMed  CAS  Google Scholar 

  • Danilo Jr P, Rosen MR. Cardiac effects of disopyramide. American Heart Journal 92: 532–536, 1976

    Article  PubMed  CAS  Google Scholar 

  • Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. European Heart Journal 5: 516–528, 1984

    Google Scholar 

  • Dhurandhar RW, Nademanee K, Goldman AM. Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases. Heart & Lung 7: 783–787, 1978

    CAS  Google Scholar 

  • DiMarco JP, Garan H, Ruskin JN. Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing. American Journal of Cardiology 47: 131–138, 1981

    Article  PubMed  CAS  Google Scholar 

  • Doherty JU, Waxman HL, Kienzle MG, Cassidy DM, Marchlinski FE, et al. Limited role of intravenous propafenone hydrochloride in the treatment of sustained ventricular tachycardia: electrophysiologic effects and results of programmed ventricular stimulation. Journal of the American College of Cardiology 4: 378–381, 1984

    Article  PubMed  CAS  Google Scholar 

  • Duff HJ, Mitchell LB, Wyse DG. Mexiletine-quinidine: frequency-dependent changes in ventricular refractoriness associated with antiarrhythmic efficacy. Abstract. Circulation 72 (Suppl. III): III–164, 1985a

    Google Scholar 

  • Duff HJ, Roden DM, Brorson L, Wood AJJ, Dawson AK, et al. Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. Journal of the American College of Cardiology 2: 1134–1140, 1983

    Article  PubMed  CAS  Google Scholar 

  • Duff HJ, Wyse DG, Manyari D, Mitchell LB. Intravenous quinidine: relations among concentration, tachyarrhythmia suppression and electrophysiologic actions with inducible sustained ventricular tachycardia. American Journal of Cardiology 55: 92–97, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Dumez D, Patmore L, Ferrandon P, Allely M, Armstrong JM. Electrophysiologic, antiarrhythmic, and cardioprotective effects of N-[3,5 dichlorophenyl] 4-[4-hydroxy-2-methoxy-phenyl] piperazine carboxamidine dihydrochloride (RS-87337). Journal of Cardiovascular Pharmacology 14: 184–193, 1989

    Article  PubMed  CAS  Google Scholar 

  • Dumoulin P, Weissenburger J, Poirier JM, Rosensztajn L, Galtet B, et al. étude des effets électrophysiologiques du sotalol intraveineux: relation avec les concentrations plasmatiques. Archives des Maladies du Coeur 78: 562–568, 1985

    CAS  Google Scholar 

  • Echt DS, Berte LE, Clusin WTT Samuelsson RG, Harrison DC, et al. Prolongation of the human cardiac monophasic action potential by sotalol. American Journal of Cardiology 50: 1082–1086, 1982

    Article  PubMed  CAS  Google Scholar 

  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. New England Journal of Medicine 324: 781–788, 1991

    Article  PubMed  CAS  Google Scholar 

  • Elharrar V, Gaum WE, Zipes DP. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. American Journal of Cardiology 39: 544–549, 1977

    Article  PubMed  CAS  Google Scholar 

  • Elharrar V, Zipes DP. Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers. Journal of Pharmacology and Experimental Therapeutics 220: 440–447, 1982

    PubMed  CAS  Google Scholar 

  • Encainide-Ventricular Tachycardia Study Group. Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction. American Journal of Cardiology 62: 571–575, 1988

    Article  Google Scholar 

  • Engel TR, Meister SG, Luck JC. Modification of ventricular tachycardia by procainamide in patients with coronary artery disease. American Journal of Cardiology 46: 1033–1038, 1980

    Article  PubMed  CAS  Google Scholar 

  • Engel TR, Soly KL, Meister SG, Frankl WS. Effect of lidocaine on right ventricular muscle refractoriness. Clinical Pharmacology and Therapeutics 19: 515–522, 1976

    PubMed  CAS  Google Scholar 

  • Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Annals of Internal Medicine 111: 107–111, 1989

    PubMed  CAS  Google Scholar 

  • Federman J, Vlietstra RE. Series on pharmacology in practice. 2. Antiarrhythmic drug therapy. Mayo Clinic Proceedings 54: 531–542, 1979

    PubMed  CAS  Google Scholar 

  • Flaker GC, Madigan NP, Alpert MA, Moser SA. Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies. American Heart Journal 108: 490–495, 1984

    Article  PubMed  CAS  Google Scholar 

  • Flecainide Ventricular Tachycardia Study Group. Treatment of resistant ventricular tachycardia with flecainide acetate. American Journal of Cardiology 57: 1299–1304, 1986

    Article  Google Scholar 

  • Flowers D, O’Gallagher D, Torres V, Miura D, Somberg JC. Flecainide: long-term treatment using a reduced dosing schedule. American Journal of Cardiology 55: 79–83, 1985

    Article  PubMed  CAS  Google Scholar 

  • Frederick LG, McDonald SJ, Garthwaite SM. Cardiovascular profile of a new anti-arrhythmic agent, SC-40230. Cardiovascular Research 23: 897–903, 1989

    Article  PubMed  CAS  Google Scholar 

  • Frey W. Weitere erfahrungen mit chinidin bei absoluter Herzunregelmässigkeit. Wiener Medizinische Wochenschrift 55: 849–853, 1918

    Google Scholar 

  • Frumin H, Kerin NZ, Rubenfire M. Classification of antiarrhythmic drugs. Journal of Clinical Pharmacology 29: 387–394,1989

    PubMed  CAS  Google Scholar 

  • Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. American Journal of Cardiology 52: 32C–36C, 1983

    Article  PubMed  CAS  Google Scholar 

  • Furukawa T, Rozanski JJ, Moroe K, Gosselin AJ, Lister JW. Efficacy of procainamide on ventricular tachycardia: relation to prolongation of refractoriness and slowing of conduction. American Heart Journal 118: 702–708, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gianelly R, von der Groeben JO, Spivack AP, Harrison DC. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. New England Journal of Medicine 277: 1215–1219, 1967

    Article  PubMed  CAS  Google Scholar 

  • Giardina EGV, Bigger Jr JT. Procaine amide against re-entrant ventricular arrhythmias. Circulation 48: 959–970, 1973

    Article  PubMed  CAS  Google Scholar 

  • Giardina EGV, Heissenbuttel RH, Bigger Jr JT. Intermittent intravenous procaine amide to treat ventricular arrhythmias. Annals of Internal Medicine 78: 183–193, 1973

    PubMed  CAS  Google Scholar 

  • Gillis AM, Wyse DG, Duff HJ, Mitchell LB. Effective antiarrhythmic drug therapy for ventricular tachycardia: importance of ventricular refractoriness. Abstract. Clinical and Investigative Medicine 12: C94, 1989

    Google Scholar 

  • Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S, the Adverse Experience Committee, and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 83: 52–60, 1991

    Article  PubMed  CAS  Google Scholar 

  • Goth A. Antiarrhythmic drugs. In Goth A (Ed.) Medical pharmacology: principles and concepts, 10th ed., p. 457, CV Mosby Company, Saint Louis, 1981

    Google Scholar 

  • Gottlieb SH, Achuff SC, Mellits ED, Gerstenblith G, Baughman KL, et al. Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. Circulation 75: 792–799, 1987

    Article  PubMed  CAS  Google Scholar 

  • Grant AO, Starmer CF, Strauss HC. Antiarrhythmic drug action: blockade of the inward sodium current. Circulation Research 55: 427–439, 1984

    Article  PubMed  CAS  Google Scholar 

  • Greene HL, Graham EL, Werner JA, Sears GK, Gross BW, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. Journal of the American College of Cardiology 2: 1114–1128, 1983

    Article  PubMed  CAS  Google Scholar 

  • Greene HL, Reid PR, Schaeffer AH. Prolongation of cardiac conduction times by intravenous aprindine in man. American Journal of Cardiology 42: 1002–1006, 1978

    Article  PubMed  CAS  Google Scholar 

  • Greenspon AJ, Volosin KJ, Greenberg RM, Jefferies L, Rotmensch HH. Amiodarone therapy: role of early and late electrophysiologic studies. Journal of the American College of Cardiology 11: 117–123, 1988

    Article  PubMed  CAS  Google Scholar 

  • Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. British Heart Journal 44: 589–595, 1980

    Article  PubMed  CAS  Google Scholar 

  • Hamer AW, Finerman Jr WB, Peter T, Mandel WJ. Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. American Heart Journal 102: 992–1000, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hansteen V, Moinichen E, Lorentsen E, Andersen A, Strom O, et al. One year’s treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. British Medical Journal 284: 155–160, 1982

    Article  PubMed  CAS  Google Scholar 

  • Harris AS, Kokernot RH. Effects of diphenylhydantoin sodium and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction. American Journal of Physiology 163: 505–516, 1950

    PubMed  CAS  Google Scholar 

  • Harrison DC. Antiarrhythmic drug classification: new science and practical applications. American Journal of Cardiology 56: 185–187, 1985

    Article  PubMed  CAS  Google Scholar 

  • Harrison DC, Winkle RA, Sami M, Mason JW. Encainide: a new and potent antiarrhythmic agent. In Harrison et al. (Eds) Cardiac arrhythmias: a decade of progress, pp. 315–330, GK Hall Medical Publishers, Boston, 1981

    Google Scholar 

  • Harron DWG, Brogden RN. Propafenone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 34: 617–647, 1987

    Article  PubMed  CAS  Google Scholar 

  • Härtel G, Louhija A, Konttinen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clinical Pharmacology and Therapeutics 15: 551–555, 1974

    PubMed  Google Scholar 

  • Heissenbuttel RH, Bigger Jr JT. The effect of oral quinidine on intraventricular conduction in man: correlation of plasma quinidine with changes in QRS duration. American Heart Journal 80: 453–462, 1970

    Article  PubMed  CAS  Google Scholar 

  • Heissenbuttel RH, Bigger Jr JT. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias. Annals of Internal Medicine 91: 229–238, 1979

    PubMed  CAS  Google Scholar 

  • Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RAJ, Camm AJ. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. British Heart Journal 48: 140–148, 1982

    Article  PubMed  CAS  Google Scholar 

  • Heng MK, Singh BN, Roche AHG, Noms RM, Mercer CJ. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. American Heart Journal 90: 487–498, 1975

    Article  PubMed  CAS  Google Scholar 

  • Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: a controlled clinical study. British Heart Journal 33:518–521,1971

    Article  PubMed  CAS  Google Scholar 

  • Hoffman BF, BiggerJr JT. Antiarrhythmic drugs. In DiPalma JR (Ed.) Drill’s pharmacology in medicine, 4th ed., pp. 824–852, McGraw-Hill Book Co., New York, 1971

    Google Scholar 

  • Holder DA, Sniderman AD, Fraser G, Fallen EL. Experience with bretylium tosylate by a hospital cardiac arrest team. Circulation 55: 541–544, 1977

    Article  PubMed  CAS  Google Scholar 

  • Hondeghem LM, Katzung BG. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochimica et Biophysica Acta 472: 373–398, 1977

    Article  PubMed  CAS  Google Scholar 

  • Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annual Review of Pharmacology and Toxicology 24: 387–423, 1984

    Article  PubMed  CAS  Google Scholar 

  • Honjo H, Watanabe T, Kamiya K, Kodama I, Toyama J. Effects of propafenone on electrical and mechanical activities of single ventricular myocytes isolated from guine-pig hearts. British Journal of Pharmacology 97: 731–738, 1989

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms. American Journal of Cardiology 58: 83C–86C, 1986

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN, Borggrefe M. Many things are not found in books or journals... but some things are! Value of electrophysiologic testing in patients with malignant ventricular arrhythmias. American Journal of Cardiology 62: 1292–1294, 1988

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN, Greenspan AM, Spielman SR, Webb CR, Morganroth J, et al. Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. American Journal of Cardiology 55: 367–371, 1985

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN, Josephson ME, Farshidi A. Human electropharmacology of tocainide, a lidocaine congener. American Journal of Cardiology 42: 276–280, 1978a

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, et al. Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation 58: 986–997, 1978b

    Article  PubMed  CAS  Google Scholar 

  • Horowitz LN, Zipes DP, Bigger Jr JT, Campbell RWF, Morganroth J, et al. Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia: a status report, 1987. American Journal of Cardiology 59: 54E-56E, 1987

    Article  Google Scholar 

  • Hugenholtz PG, Hagemeijer F, Lubsen J, Glazer B, Van Durme JP, et al. One year follow-up in patients with persistent ventricular dysrhythmias after myocardial infarction treated with aprindine or placebo. In Sandoe et al. (Eds) Management of ventricular tachycardia: role of mexiletine, pp. 572–578, Excerpta Medica, Amsterdam, 1978

    Google Scholar 

  • Huikuri HV, Cox M, Interian A, Kessler KM, Glicksman F, et al. Efficacy of intravenous propranolol for suppression of inducibility of ventricular tachyarrhythmias with different electrophysiologic characteristics in coronary artery disease. American Journal of Cardiology 64: 1305–1309, 1989

    Article  PubMed  CAS  Google Scholar 

  • Ikeda N, Singh BN, Davis LD, Hauswirth O. Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. Journal of the American College of Cardiology 5: 303–310, 1985

    Article  PubMed  CAS  Google Scholar 

  • IMPACT Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Journal of the American College of Cardiology 4: 1148–1163, 1984

    Article  Google Scholar 

  • Ito M, Onodera S, Hashimoto J, Noshiro H, Shinoda S, et al. Effect of disopyramide on initiation of atrial fibrillation and relation to effective refractory period. American Journal of Cardiology 63: 561–566, 1989

    Article  PubMed  CAS  Google Scholar 

  • Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Progress in cardiovascular Diseases 31: 115–172, 1988

    Article  PubMed  CAS  Google Scholar 

  • Jackman WM, Zipes DP, Naccarelli GV, Rinkenberger RL, Heger JJ, et al. Electrophysiology of oral encainide. American Journal of Cardiology 49: 1270–1278, 1982

    Article  PubMed  CAS  Google Scholar 

  • Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. PhysiologicalReviews 69: 1049–1169, 1989

    PubMed  CAS  Google Scholar 

  • Jennings G, Jones MBS, Besterman EMM, Model DG, Turner PP, et al. Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. Lancet 1: 51–54, 1976

    Article  PubMed  CAS  Google Scholar 

  • Jensen RA, Katzung BG. Electrophysiological actions of diphenylhydantoin on rabbit atria. Circulation Research 26: 17–27, 1970

    Article  PubMed  CAS  Google Scholar 

  • Jewitt DE, Kishon Y, Thomas M. Lignocaine in the management of arrhythmias after acute myocardial infarction. Lancet 1: 266–270, 1968

    Article  Google Scholar 

  • Johnson EA. The effects of quinidine, procaine amide and pyrilamine on the membrane resting and action potential of guinea pig ventricular muscle fibers. Journal of Pharmacology and Experimental Therapeutics 108: 237–244, 1956

    Google Scholar 

  • Josephson ME, Caracta AR, Lau SH, Gallagher JJ, Damato AN. Electrophysiological evaluation of disopyramide in man. American Heart Journal 86: 771–780, 1973

    Article  PubMed  CAS  Google Scholar 

  • Josephson ME, Caracta AR, Ricciutti MA, Lau SH, Damato AN. Electrophysiologic properties of procainamide in man. American Journal of Cardiology 33: 596–603, 1974a

    Article  PubMed  CAS  Google Scholar 

  • Josephson ME, Seides SF, Batsford WP, Weisfogel GM, Akhtar M, et al. The electrophysiological effects of intramuscular quinidine on the atrioventricular conducting system in man. American Heart Journal 87: 55–64, 1974b

    Article  PubMed  CAS  Google Scholar 

  • Julian DG, Jackson FS, Prescott RJ, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1: 1142–1150, 1982

    Article  PubMed  CAS  Google Scholar 

  • Kadish AH, Marchlinski FE, Josephson ME, Buxton AE. Amiodarone: correlation of early and late electrophysiologic studies with outcome. American Heart Journal 112: 1134–1140, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kempf Jr FC, Josephson ME. Cardiac arrest recorded on ambulatory electrocardiograms. American Journal of Cardiology 53: 1577–1582, 1984

    Article  PubMed  Google Scholar 

  • Kermaier AI, Hayakawa H, Mandel WJ. Effect of lidocaine on the scalar orthogonal electrocardiogram. American Heart Journal 84: 366–370, 1972

    Article  PubMed  CAS  Google Scholar 

  • Kesteloot H, Stroobandt R. Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug. European Journal of Clinical Pharmacology 16: 323–326, 1979

    Article  PubMed  CAS  Google Scholar 

  • Kienzle MG, Martins JB, Wendt DJ, Constantin L, Hopson R, et al. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type 1 antiarrhythmic drugs. American Journal of Cardiology 61: 1012–1017, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kim SG, Felder SD, Waspe LE, Fisher JD. Electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class 1A agents for refractory recurrent ventricular tachycardias or ventricular fibrillation. American Journal of Cardiology 58: 485–490, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kim SG, Seiden SW, Matos JA, Waspe LE, Fisher JD. Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of class 1A antiarrhytmic agents in patients with ventricular tachycardia. Journal of the American College of Cardiology 6: 539–544, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kirkorian G, Touboul P, Atallah G. Electrophysiologic effects of propranolol in intraventricular conduction disturbance. American Journal of Cardiology 61: 341–345, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. American Journal of Cardiology 57:43F–49F, 1986

    Article  PubMed  CAS  Google Scholar 

  • Kniffen FJ, Lomas TE, Counsell RE, Lucchesi BR. The antiarrhythmic and antifibrillatory actions of bretylium and its o-iodobenzyl trimethylammonium analog, UM-360. Journal of Pharmacology and Experimental Therapeutics 192: 120-.128, 1975

    PubMed  CAS  Google Scholar 

  • Koch-Weser J. Drug therapy: disopyramide. New England Journal of Medicine 300: 957–962, 1979

    Article  PubMed  CAS  Google Scholar 

  • Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, DeSanctis RW. Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. New England Journal of Medicine 281: 1253–1260, 1969

    Article  PubMed  CAS  Google Scholar 

  • Kohlhardt M, Seifert C. Inhibition of Vmax of the action potential by propafenone and its voltage-, time- and pH-dependence in mammalian ventricular myocardium. Naunyn-Schmiedeberg’s Archives of Pharmacology 315: 55–62, 1980

    Article  PubMed  CAS  Google Scholar 

  • Kopelman HA, Woosley RL, Lee JT, Roden DM, Echt DS. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. American Journal of Cardiology 61: 1006–1011, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kosowsky BD, Taylor J, Lown B, Ritchie RF. Long-term use of procaine amide following acute myocardial infarction. Circulation 47: 1204–1210, 1973

    Article  PubMed  CAS  Google Scholar 

  • Kossmann CE. Torsade de pointes: an addition to the nosography of ventricular tachycardia. American Journal of Cardiology 42: 1054–1056, 1978

    Article  PubMed  CAS  Google Scholar 

  • Kunze KP, Kuck KH, Schlüter M, Kuch B, Bleifeld W. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway. American Journal of Cardiology 54: 323–329, 1984

    Article  PubMed  CAS  Google Scholar 

  • Kus T, Sasyniuk BI. Electrophysiological actions of disopyramide phosphate on canine ventricular muscle and Purkinje fibers. Circulation Research 37: 844–854, 1975

    Article  PubMed  CAS  Google Scholar 

  • Lal R, Chapman PD, Naccarelli GV, Troup PJ, Rinkenberger RL, et al. Short- and long-term experience with flecainide acetate in the management of refractory life-threatening ventricular arrhythmias. Journal of the American College of Cardiology 6: 772–779, 1985

    Article  PubMed  CAS  Google Scholar 

  • Lazzara R, Hope RR, El-Sherif N, Scherlag BJ. Effects of lidocaine on hypoxic and ischemic cardiac cells. American Journal of Cardiology 41: 872–879, 1978

    Article  PubMed  CAS  Google Scholar 

  • Lederman SN, Wenger TL, Bolster DE, Strauss HC. Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. Journal of Cardiovascular Pharmacology 13: 541–546, 1989

    PubMed  CAS  Google Scholar 

  • Lewis T. The value of quinidine in cases of auricular fibrillation and methods of studying the clinical reaction/American Journal of the Medical Sciences 163: 781–794, 1922

    CAS  Google Scholar 

  • Libersa CC, Lekieffre JP, Caron JF, Poirier JM, Pladys AM, et al. Electrophysiological effects of encainide and its metabolites in 11 patients. Journal of Cardiovascular Pharmacology 7: 1077–1082, 1985

    Article  PubMed  CAS  Google Scholar 

  • Lie KI, Wellens HJ, van Capelle FJ, Durrer D. Lidocaine in the prevention of primary ventricular fibrillation. New England Journal of Medicine 291: 1324–1326, 1974

    Article  PubMed  CAS  Google Scholar 

  • Ling GN, Gerard RW. The normal membrane potential of frogsartorius fibers. Journal of Cellular and Comparative Physiology 34: 383–396, 1949

    Article  CAS  Google Scholar 

  • Ludmer PL, McGowan NE, Antman EM, Friedman PL. Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. Journal of the American College of Cardiology 9: 1357–1363, 1987

    Article  PubMed  CAS  Google Scholar 

  • Manouvrier J, Sagot M, Caron C, Vaskmann G, Leroy R, et al. Nine cases of torsades de pointes with bepridil administrattion. American Heart Journal 111: 1005–1007, 1986

    Article  PubMed  CAS  Google Scholar 

  • Manz M, Steinbeck G, Nitsch J, Lüderitz B. Treatment of recurrent sustained ventricular tachycardia with mexiletine and disopyramide. British Heart Journal 49: 222–228, 1983

    Article  PubMed  CAS  Google Scholar 

  • Marchlinski FE, Buxton AE, Vassallo JA, Waxman HL, Cassidy DM, et al. Comparative electrophysiologic effects of intravenous and oral procainamide in patients with sustained ventricular arrhythmias. Journal of the American College of Cardiology 4: 1247–1254, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mark LC, Kayden HJ, Steele JM, Cooper JR, Berlin I, et al. The physiological disposition and cardiac effects of procaine amide. Journal of Pharmacology and Experimental Therapeutics 102: 5–15, 1951

    PubMed  CAS  Google Scholar 

  • Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circulation Research 55: 277–285, 1984

    Article  CAS  Google Scholar 

  • Mason JW, Peters FA. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation 63: 670–675, 1981

    Article  PubMed  CAS  Google Scholar 

  • Mason JW, Swerdlow CD, Mitchell LB. Efficacy of verapamil in chronic, recurrent ventricular tachycardia. American Journal of Cardiology 51: 1614–1617, 1983

    Article  PubMed  CAS  Google Scholar 

  • Mattioni TA, Zheutlin TA, Sarmiento JJ, Parker M, Lesch M, et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Annals of Internal Medicine 111: 574–580, 1989

    PubMed  CAS  Google Scholar 

  • McComish M, Robinson C, Kitson D, Jewitt DE. Clinical electrophysiological effects of mexiletine. Postgraduate Medical Journal 53 (Suppl. 1): 85–91, 1977

    PubMed  Google Scholar 

  • McGovern B, Garan H, Malacoff RF, DiMarco JP, Grant G, et al. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. American Journal of Cardiology 53: 1558–1563, 1984

    Article  PubMed  CAS  Google Scholar 

  • McKibbin JK, Pocock WA, Barlow JB, Millar RNS, Obel IWP. Sotalol, hypokalaemia, syncope, and torsade de pointes. British Heart Journal 51: 157–162, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mercer EN, Osborae JA. The current status of diphenylhydantoin in heart disease. Annals of Internal Medicine 67: 1084–1107, 1967

    PubMed  CAS  Google Scholar 

  • Michelson EL, Dreifus LS. Newer antiarrhythmic drugs. Medical Clinics of North America 72: 275–319, 1988

    PubMed  CAS  Google Scholar 

  • Mines GR. On circulating excitations in heart muscles and their possible relation to tachycardia and fibrillation. Proceedings and Transactions of the Royal Society of Canada 8: 43–52, 1914

    Google Scholar 

  • Moe GK, Abildskov JA. Antiarrhythmic drugs. In Goodman et al. (Eds) The pharmacological basis of therapeutics, 3rd ed., pp. 699–715, The Macmillan Company, New York, 1965

    Google Scholar 

  • Moe GK, Abildskov JA. Antiarrhythmic drugs. In Goodman et al. (Eds) The pharmacological basis of therapeutics, 4th ed., pp. 709–727, The Macmillan Company, New York, 1970

    Google Scholar 

  • Moe GK, Abildskov JA. Antiarrhythmic drugs. In Goodman et al. (Eds) The pharmacological basis of therapeutics, 5th ed., pp. 683–704, Macmillan Publishing Co. Inc., New York, 1975

    Google Scholar 

  • Moosvi AR, Goldstein S, VanderBrug Medendorp S, Landis JR, Wolfe RA, et al. Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease. American Journal of Cardiology 65: 1192–1197, 1990

    Article  PubMed  CAS  Google Scholar 

  • Morady F, DiCarlo LA, Krol RB, Baerman JM, de Buitleir M. Acute and chronic effects of amiodarone on ventricular refractoriness, intraventricular conduction and ventricular tachycardia induction. Journal of the American College of Cardiology 7: 148–157, 1986

    Article  PubMed  CAS  Google Scholar 

  • Morganroth J. Risk factors for the development of proarrhythmic events. American Journal of Cardiology 59: 32E-37E, 1987

    Article  Google Scholar 

  • Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. Journal of the American College of Cardiology 8: 607–615, 1986

    Article  PubMed  CAS  Google Scholar 

  • Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebocontrolled comparison. Circulation 69: 740–747, 1984

    Article  PubMed  CAS  Google Scholar 

  • Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. New England Journal of Medicine 319: 385–392, 1988

    Article  Google Scholar 

  • Multicenter International Study. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. British Medical Journal 3: 735–740, 1975

    Article  Google Scholar 

  • Naccarelli GV, Fineberg NS, Zipes DP, Heger JJ, Duncan G, et al. Amiodarone: risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. Journal of the American College of Cardiology 6: 814–821, 1985

    Article  PubMed  CAS  Google Scholar 

  • Nademanee K, Feld G, Hendrickson JA, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 72: 555–564, 1985

    Article  PubMed  CAS  Google Scholar 

  • Nademanee K, Hendrickson JA, Kannan R, Singh BN. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. American Heart Journal 103: 950–959, 1982

    Article  PubMed  CAS  Google Scholar 

  • Nademanee K, Singh BN, Hendrickson J, Intarachot V, Lopez B, et al. Amiodarone in refractory life-threatening ventricular arrhythmias. Annals of Internal Medicine 98: 577–584, 1983

    PubMed  CAS  Google Scholar 

  • Nattel S, Euler DE, Spear JF, Moore EN. Autonomie control of ventricular refractoriness. American Journal of Physiology 241: H878–H882, 1981a

    PubMed  CAS  Google Scholar 

  • Nattel S, Feder-Elituv R, Matthews C, Nayebpour M, Talajic M. Concentration dependence of class III and beta-adrenergic blocking effects of sotalol in anesthetized dogs. Journal of the American College of Cardiology 13: 1190–1194, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Pedersen DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovascular Research 15: 80–85, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Quantz MA. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovascular Research 22: 808–817, 1988

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 36: 121–131, 1988

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. Circulation 76: 442–449, 1987

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Waters D. What is an antiarrhythmic drug? From clinical trials to fundamental concepts. American Journal of Cardiology 66: 96–100, 1990

    Article  PubMed  CAS  Google Scholar 

  • Nattel S, Zeng FD. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. Journal of Pharmacology and Experimental Therapeutics 229: 283–291, 1984

    PubMed  CAS  Google Scholar 

  • Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J. Sotalol prolongation of the QTC interval in hypertensive patients. Clinical Pharmacology and Therapeutics 32: 25–32, 1982

    Article  PubMed  CAS  Google Scholar 

  • Neuvonen PJ, Elonen E, Vuorenmaa T, Laakso M. Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. European Journal of Clinical Pharmacology 20: 85–89, 1981

    Article  PubMed  CAS  Google Scholar 

  • Niarchos AP. Disopyramide: serum level and arrhythmia conversion. American Heart Journal 92: 57–64, 1976

    Article  PubMed  CAS  Google Scholar 

  • Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New England Journal of Medicine 304: 801–807, 1981

    Article  Google Scholar 

  • Olsson SB, Edvardsson N. Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation. American Heart Journal 102: 864–871, 1981

    Article  PubMed  CAS  Google Scholar 

  • Palileo EV, Welch W, Hoff J, Strasberg B, Bauernfeind RA, et al. Lack of effectiveness of oral mexiletine in patients with drug-refractory paroxysmal sustained ventricular tachycardia. American Journal of Cardiology 50: 1075–1081, 1982

    Article  PubMed  CAS  Google Scholar 

  • Panidis IP, Morganroth J. Sudden death in hospitalized patientscardiac rhythm disturbances detected by ambulatory electro-cardiographic monitoring. Journal of the American College of Cardiology 2: 798–805, 1983

    Article  PubMed  CAS  Google Scholar 

  • Peter T, Ross D, Duffield A, Luxton M, Harper R, et al. Effect on survival after myocardial infarction of long-term treatment with phenytoin. British Heart Journal 40: 1356–1360, 1978

    Article  PubMed  CAS  Google Scholar 

  • Pitt A, Lipp H, Anderson ST. Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet 1: 612–616, 1971

    Article  PubMed  CAS  Google Scholar 

  • Platia EV, Estes NAM, Heine DL, Griffith LSC, Garan H, et al. Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. American Journal of Cardiology 55: 956–962, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rae AP, Greenspan AM, Spielman SR, Sokoloff NM, Webb CR, et al. Antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with coronary artery disease as assessed by electrophysiologic studies. American Journal of Cardiology 55: 1494–1499, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rae AP, Kay HR, Horowitz LN, Spielman SR, Greenspan AM. Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. Journal of the American College of Cardiology 12: 131–139, 1988

    Article  PubMed  CAS  Google Scholar 

  • Ranger S, Talajic M, Lemery R, Roy D, Nattel S. Amplification of flecainide-induced ventricular conduction slowing by exercise: a potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 79: 1000–1006, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rankin AC, Pringle SD, Cobbe SM. Acute treatment of torsades de pointes with amiodarone: proarrhythmic and antiarrhythmic association of QT prolongation. American Heart Journal 119: 185–186, 1990

    Article  PubMed  CAS  Google Scholar 

  • Reddy CP, Kuo CS, Jivrajka V. Effect of amiodarone on electric induction, morphology, and rate of ventricular tachycardia and its relation to clinical efficacy. PACE 7: 1055–1062, 1984

    Article  PubMed  CAS  Google Scholar 

  • Reiter MJ, Easley AR, Mann DE. Efficacy of class 1b (lidocainelike) antiarrhythmic agents for prevention of sustained ventricular tachycardia secondary to coronary artery disease. American Journal of Cardiology 59: 1319–1324, 1987

    Article  PubMed  CAS  Google Scholar 

  • Reiter MJ, Higgins SL, Payne AG, Mann DE. Effects of quinidine versus procainamide on the QT interval. American Journal of Cardiology 58: 512–516, 1986

    Article  PubMed  CAS  Google Scholar 

  • Rinkenberger RL, Prystowsky EN, Jackman WM, Naccarelli GV, Heger JJ, et al. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiological studies: identification of drugs that exacerbate tachycardia and potential mechanisms. American Heart Journal 103: 177–184, 1982

    Article  PubMed  CAS  Google Scholar 

  • Rizzon P, Di Biase M, Calabrese P, Brindicci G, Chiddo A. Electrophysiologic evaluation of intravenous verapamil in man. European Journal of Cardiology 6: 179–194, 1977

    PubMed  CAS  Google Scholar 

  • Roden DM, Reele SB, Higgins SB, Mayol RF, Gammans RE, et al. Total suppression of ventricular arrhythmias by encainide. New England Journal of Medicine 302: 877–882, 1980

    Article  PubMed  CAS  Google Scholar 

  • Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. Journal of the American College of Cardiology 8: 73A–78A, 1986

    Article  PubMed  CAS  Google Scholar 

  • Roos JC, Paalman ACA, Dunning AJ. Electrophysiological effects of mexiletine in man. British Heart Journal 38: 1262–1271, 1976

    Article  PubMed  CAS  Google Scholar 

  • Rosen KM, Lau SH, Weiss MB, Damato AN. The effect of lidocaine on atrioventricular and intraventricular conduction in man. American Journal of Cardiology 25: 1–5, 1970

    Article  PubMed  CAS  Google Scholar 

  • Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent American Journal of Cardiology 38: 934–944, 1976

    Article  PubMed  CAS  Google Scholar 

  • Roy D, Montigny M, Klein GJ, Sharma AD, Cassidy D. Electrophysiologic effects and long-term efficacy of bepridil for recurrent supraventricular tachycardias. American Journal of Cardiology 59: 89–92, 1987

    Article  PubMed  CAS  Google Scholar 

  • Roy PR, Spurrell RAJ, Sowton E. The effect of verapamil on the cardiac conduction system in man Postgraduate Medical Journal 50: 270–275, 1974

    Google Scholar 

  • Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, et al. Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. Journal of the American College of Cardiology 13: 145–152, 1989

    Article  PubMed  CAS  Google Scholar 

  • Rydén L, Amman K, Conradson TB, Hofvendahl S, Mortensen O, et al. Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. American Heart Journal 100: 1006–1012, 1980

    Article  PubMed  Google Scholar 

  • Saksena S, Klein GJ, Kowey PR, Calvo RA, Boccadamo R, et al. Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias. American Journal of Cardiology 59: 307–312, 1987

    Article  PubMed  CAS  Google Scholar 

  • Saksena S, Rothbart ST, Shah Y, Cappello G. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. American Journal of Cardiology 54: 347–352, 1984

    Article  PubMed  CAS  Google Scholar 

  • Sami M, Mason JW, Peters F, Harrison DC. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent. American Journal of Cardiology 44: 526–532, 1979

    Article  PubMed  CAS  Google Scholar 

  • Sasyniuk BI, Kus T. Comparison of the effects of lidocaine on electrophysiological properties of normal Purkinje fibers and those surviving acute myocardial infarction. Abstract. Federation Proceedings 33: 476, 1974

    Google Scholar 

  • Scagliotti D, Strasberg B, Hai HA, Kehoe R, Rosen K. Aprindine-induced polymorphous ventricular tachycardia. American Journal of Cardiology 49: 1297–1300, 1982

    Article  PubMed  CAS  Google Scholar 

  • Schmitt C, Brachmann J, Waldecker B, Rizos I, Senges J, et al. Amiodarone in patients with recurrent sustained ventricular tachyarrhythmias: results of programmed electrical stimulation and long-term clinical outcome in chronic treatment. American Heart Journal 114: 279–283, 1987

    Article  PubMed  CAS  Google Scholar 

  • Schoenfeld MH, Whitford E, McGovern B, Garan H, Ruskin JN. Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques. American Heart Journal 107: 1071–1078, 1984

    Article  PubMed  CAS  Google Scholar 

  • Sekiya A, Vaughan Williams EM. A comparison of the antifibrillatory actions and effect on intracellular cardiac potentials of pronethalol, disopyramide and quinidine. British Journal of Pharmacology and Chemotherapy 21: 473–481, 1963

    PubMed  CAS  Google Scholar 

  • Selzer A, Wray HW. Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30: 17–26, 1964

    Article  PubMed  CAS  Google Scholar 

  • Senges J, Lengfelder W, Jauernig R, Czygan E, Brachmann J, et al. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Circulation 69: 577–584, 1984

    Article  PubMed  CAS  Google Scholar 

  • Shen EN, Sung RJ, Morady F, Schwartz AB, Scheinman MM, et al. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. Journal of the American College of Cardiology 3: 1291–1297, 1984

    Article  PubMed  CAS  Google Scholar 

  • Singh BN. Amiodarone: Historical development and pharmacologic profile. American Heart Journal 106: 788–797, 1983

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Deedwania P, Nadamanee K, Ward A, Sorkin EM. Sotalol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 34: 311–349, 1987

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. American Heart Journal 87: 367–382, 1974

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Kaplinsky E, Kirsten E, Guerrero J and the Propafenone Multi-Center Research Group. Effects of propafenone on ventricular arrhythmias: double-blind, parallel, randomized, placebo-controlled dose ranging study. American Heart Journal 116: 1542–1551, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Roche AHG. Effects of intravenous verapamil on hemodynamics in patients with heart disease. American Heart Journal 94: 593–599, 1977

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. British Journal of Pharmacology 39: 657–667, 1970a

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action: effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. British Journal of Pharmacology 39: 675–687, 1970b

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Vaughan Williams EM. Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circulation Research 29: 286–295, 1971

    Article  PubMed  CAS  Google Scholar 

  • Singh BN, Vaughan Williams EM. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovascular Research 6: 109–119, 1972

    Article  PubMed  CAS  Google Scholar 

  • Singh SN, Cohen A, Chen Y, Wish M, Thoben-O’Grady L, et al. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. American Journal of Cardiology 62: 399–402, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Sloskey GE. Amiodarone: a unique antiarrhythmic agent. Clinical Pharmacy 2: 330–339, 1983

    PubMed  CAS  Google Scholar 

  • Southworth JL, McKusick VA, PeirceII EC, Rawson FL. Ventricular fibrillation precipitated by cardiac catheterization. Journal of the American Medical Association 143: 717–720, 1950

    Article  PubMed  CAS  Google Scholar 

  • Spurrell RAJ, Thorburn CW, Camm J, Sowton E, Deuchar DC. Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome. British Heart Journal 3.7: 861–867, 1975

    Article  Google Scholar 

  • Stanton MS, Prystowsky EN, Fineberg NS, Miles WM, Zipes DP, et al. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation. Journal of the American College of Cardiology 14: 209–215, 1989

    Article  PubMed  CAS  Google Scholar 

  • Stapczynski JS. Update on antiarrhythmic drugs in emergency medicine. Emergency Medicine Clinics of North America 6: 289–315, 1988

    PubMed  CAS  Google Scholar 

  • Steinbeck G, Bach P, Haberl R. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evalution by programmed stimulation and ambulatory electrocardiogram. Journal of the American College of Cardiology 8: 949–958, 1986

    Article  PubMed  CAS  Google Scholar 

  • Steinberg MI, Greenspan K. Intracellular electrophysiological alterations in canine cardiac conducting tissue induced by aprindine and lignocaine. Cardiovascular Research 10: 236–244, 1976

    Article  PubMed  CAS  Google Scholar 

  • Strasberg B, Sclarovsky S, Erdberg A, Duffy CE, Lam W, et al. Procainamide-induced polymorphous ventricular tachycardia. American Journal of Cardiology 47: 1309–1314, 1981

    Article  PubMed  CAS  Google Scholar 

  • Sung RJ, Shapiro WA, Shen EN, Morady F, Davis J. Effects of verapamil on ventricular tachycardias possibly caused by reentry, automaticity, and triggered activity. Journal of Clinical Investigation 72: 350–360, 1983

    Article  PubMed  CAS  Google Scholar 

  • Swerdlow CD, Yu JO, Jacobson E, Mann S, Winkle RA, et al. Safety and efficacy of intravenous quinidine. American Journal of Medicine 75: 36–42, 1983

    Article  PubMed  CAS  Google Scholar 

  • Takanaka C, Singh BN. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. Journal of the American College of Cardiology 15: 213–221, 1990

    Article  PubMed  CAS  Google Scholar 

  • Talajic M, DeRoode MR, Nattel S. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 75: 265–271, 1987

    Article  PubMed  CAS  Google Scholar 

  • Talajic M, Nattel S, Davies M, McCans J. Attenuation of class 3 and sinus node effects of amiodarone by experimental hypothyroidism. Journal of Cardiovascular Pharmacology 13: 447–450, 1989

    Article  PubMed  CAS  Google Scholar 

  • Timmis GC, Westveer DC, Nelson TA, Hauser AM, Stewart JR, et al. Arrhythmias and conduction defects. In Cardiovascular Review 1984, pp. 438–439, Academic Press, Inc., 1984

  • Torres V, Flowers D, Miura D, Somberg J. Intravenous quinidine by intermittent bolus for electrophysiologic studies in patients with ventricular tachycardia. American Heart Journal 108: 1437–1442, 1984

    Article  PubMed  CAS  Google Scholar 

  • Touboul P, Atallah G, Kirkorian G, Lamaud M, Moleur P. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. American Heart Journal 107: 888–895, 1984

    Article  PubMed  CAS  Google Scholar 

  • Toyama J, Kodama I, Honjo H, Kamiya K. Electrophysiological effects of OPC-88117, a new antiarrhythmic agent on papillary muscles and single ventricular myocytes isolated from guinea-pig hearts. British Journal of Pharmacology 98: 177–185, 1989

    Article  PubMed  CAS  Google Scholar 

  • Troup PJ, Zipes DP. Aprindine treatment of recurrent ventricular tachycardia in patients with mitral valve prolapse. American Heart Journal 97: 322–328, 1979

    Article  PubMed  CAS  Google Scholar 

  • Varro A, Elharrar V, Surawicz B. Frequency-dependent effects of several class I antiarrhythmic drugs on Vmax of action potential upstroke in canine cardiac Purkinje fibers. Journal of Cardiovascular Pharmacology 7: 482–492, 1985

    Article  PubMed  CAS  Google Scholar 

  • Varro A, Nakaya Y, Elharrar V, Surawicz B. Effect of antiarrhythmic drugs on the cycle length-dependent action potential duration in dog Purkinje and ventricular muscle fibers. Journal of Cardiovascular Pharmacology 8: 178–185, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vaughan Williams EM. The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records. British Journal of Pharmacology 13: 276–287, 1958

    CAS  Google Scholar 

  • Vaughan Williams EM. A classification of antiarrhythmic actions reassesssed after a decade of new drugs. Journal of Clinical Pharmacology 24: 129–147, 1984

    PubMed  CAS  Google Scholar 

  • Veltri EP, Reid PR, Platia EV, Griffith LSC. Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. American Journal of Cardiology 55: 375–379, 1985

    Article  PubMed  CAS  Google Scholar 

  • Verdonck F, Vereecke J, Vleugels A. Electrophysiological effects of aprindine on isolated heart preparations. European Journal of Pharmacology 26: 338–347, 1974

    Article  PubMed  CAS  Google Scholar 

  • Wallace AG, Cline RE, Sealy WC, Young Jr WG, Troyer Jr WG. Electrophysiologic effects of quinidine: studies using chronically implanted electrodes in awake dogs with and without cardiac denervation. Circulation Research 19: 960–969, 1966

    Article  PubMed  CAS  Google Scholar 

  • Wang T, Bergstrand RH, Thompson KA, Siddoway LA, DuffHJ, et al. Concentration-dependent pharmacologic properties of sotalol. American Journal of Cardiology 57: 1160–1165, 1986

    Article  PubMed  CAS  Google Scholar 

  • Wang Z, Pelletier LC, Talajic M, Nattel S. The effects of flecainide and quinidine on human atrial action potentials. Circulation 82: 274–283, 1990

    Article  PubMed  CAS  Google Scholar 

  • Waspe LE, Waxman HL, Buxton AE, Josephson ME. Mexiletine for control of drug-resistant ventricular tachycardia: clinical and electrophysiologic results in 44 patients. American Journal of Cardiology 51: 1175–1181, 1983

    Article  PubMed  CAS  Google Scholar 

  • Waxman HL. The efficacy of amiodarone for ventricular arrhythmias cannot be predicted with clinical electrophysiological studies. International Journal of Cardiology 3: 76–80, 1983

    Article  PubMed  CAS  Google Scholar 

  • Waxman HL, Groh WC, Marchlinski FE, Buxton AE, Sadowski LM, et al. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients. American Journal of Cardiology 50: 1066–1074, 1982

    Article  PubMed  CAS  Google Scholar 

  • Webb CR, Morganroth J, Senior S, Spielman SR, Greenspan AM, et al. Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia. Journal of the American College of Cardiology 8: 214–220, 1986

    Article  PubMed  CAS  Google Scholar 

  • Wehr M, Noll B, Krappe J. Flecainide-induced aggravation of ventricular arrhythmias. American Journal of Cardiology 55: 1643–1644, 1985

    Article  PubMed  CAS  Google Scholar 

  • Weidmann S. Effects of calcium ions and local anaesthetics on electrical properties of Purkinje fibres. Journal of Physiology 129: 568–582, 1955

    PubMed  CAS  Google Scholar 

  • Wellens HJJ, Bär FWHM, Lie KI, Düren DR, Dohmen HJ. Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia. American Journal of Cardiology 40: 579–585, 1977

    Article  PubMed  CAS  Google Scholar 

  • Wellens HJJ, Brugada P, Abdullah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 69: 120–124, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wilcox RG, Hampton JR, Banks DC, Birkhead J, Brooksby I, et al. Trial of early nifedipine treatment in patients with suspected myocardial infarction (the TRENT study). Abstract. British Heart Journal 55: 506, 1986

    Google Scholar 

  • Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, Werko L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Lancet 2: 1157–1160, 1974

    Article  PubMed  CAS  Google Scholar 

  • Winkle RA, Mason JW, Griffin JC, Ross D. Malignant ventricular tachyarrhythmias associated with the use of encainide. American Heart Journal 102: 857–863, 1981a

    Article  PubMed  CAS  Google Scholar 

  • Winkle RA, Peters F, Kates RE, Tucker C, Harrison DC. Clinical pharmcology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Circulation 64: 290–296, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Wit AL, Steiner C, Damato AN. Electrophysiologic effects of bretylium tosylate on single fibers of the canine specialized conducting system and ventricle. Journal of Pharmacology and Experimental Therapeutics 173: 344–356, 1970

    PubMed  CAS  Google Scholar 

  • Woske H, Beiford J, Fastier FN, Brooks CMcC. The effect of procaine amide on excitability, refractoriness and conduction in the mammalian heart. Journal of Pharmacology and Experimental Therapeutics 107: 134–139, 1953

    PubMed  CAS  Google Scholar 

  • Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. Journal of Pharmacology and Experimental Therapeutics 237: 9–17, 1986

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Montreal Heart Institute, 5000 Belanger Street East, Montréal, Québec, HIT 1C8, Canada

    Stanley Nattel

  2. Departments of Pharmacology and Therapeutics and Medicine, McGill University, Montréal, Québec, Canada

    Stanley Nattel

Authors
  1. Stanley Nattel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nattel, S. Antiarrhythmic Drug Classifications. Drugs 41, 672–701 (1991). https://doi.org/10.2165/00003495-199141050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199141050-00002

Keywords

Search

Navigation